Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Sep;81(2):269–276. doi: 10.1038/sj.bjc.6690687

Potent interaction of flavopiridol with MRP1

J H Hooijberg 1, H J Broxterman 1, G L Scheffer 2, C Vrasdonk 1, M Heijn 1, M C de Jong 2, R J Scheper 2, J Lankelma 1, HM Pinedo 1
PMCID: PMC2362861  PMID: 10496352

Abstract

The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its anti-proliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC4/ADR. The accumulation of daunorubicin in GLC4/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 μM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol. © 1999 Cancer Research Campaign

Keywords: multidrug resistance, MRP1, (iso)flavonoids, flavopiridol, ATPase

Full Text

The Full Text of this article is available as a PDF (132.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987 Apr 25;262(12):5592–5595. [PubMed] [Google Scholar]
  2. Bible K. C., Kaufmann S. H. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. 1997 Aug 15;57(16):3375–3380. [PubMed] [Google Scholar]
  3. Bokkenheuser V. D., Shackleton C. H., Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J. 1987 Dec 15;248(3):953–956. doi: 10.1042/bj2480953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bors W., Saran M. Radical scavenging by flavonoid antioxidants. Free Radic Res Commun. 1987;2(4-6):289–294. doi: 10.3109/10715768709065294. [DOI] [PubMed] [Google Scholar]
  5. Broxterman H. J., Giaccone G., Lankelma J. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol. 1995 Nov;7(6):532–540. doi: 10.1097/00001622-199511000-00011. [DOI] [PubMed] [Google Scholar]
  6. Broxterman H. J., Kuiper C. M., Schuurhuis G. J., Tsuruo T., Pinedo H. M., Lankelma J. Increase of daunorubicin and vincristine accumulation in multidrug resistant human ovarian carcinoma cells by a monoclonal antibody reacting with P-glycoprotein. Biochem Pharmacol. 1988 Jun 15;37(12):2389–2393. doi: 10.1016/0006-2952(88)90365-6. [DOI] [PubMed] [Google Scholar]
  7. Bulter J., Spielberg S. P., Schulman J. D. Reduction of disulfide-containing amines amino acids, and small peptides. Anal Biochem. 1976 Oct;75(2):674–675. doi: 10.1016/0003-2697(76)90129-9. [DOI] [PubMed] [Google Scholar]
  8. Carlson B. A., Dubay M. M., Sausville E. A., Brizuela L., Worland P. J. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 1996 Jul 1;56(13):2973–2978. [PubMed] [Google Scholar]
  9. Chang X. B., Hou Y. X., Riordan J. R. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem. 1997 Dec 5;272(49):30962–30968. doi: 10.1074/jbc.272.49.30962. [DOI] [PubMed] [Google Scholar]
  10. Cole S. P., Bhardwaj G., Gerlach J. H., Mackie J. E., Grant C. E., Almquist K. C., Stewart A. J., Kurz E. U., Duncan A. M., Deeley R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 1992 Dec 4;258(5088):1650–1654. doi: 10.1126/science.1360704. [DOI] [PubMed] [Google Scholar]
  11. Cole S. P., Deeley R. G. Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP. Bioessays. 1998 Nov;20(11):931–940. doi: 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J. [DOI] [PubMed] [Google Scholar]
  12. Cotelle N., Bernier J. L., Hénichart J. P., Catteau J. P., Gaydou E., Wallet J. C. Scavenger and antioxidant properties of ten synthetic flavones. Free Radic Biol Med. 1992 Sep;13(3):211–219. doi: 10.1016/0891-5849(92)90017-b. [DOI] [PubMed] [Google Scholar]
  13. Critchfield J. W., Welsh C. J., Phang J. M., Yeh G. C. Modulation of adriamycin accumulation and efflux by flavonoids in HCT-15 colon cells. Activation of P-glycoprotein as a putative mechanism. Biochem Pharmacol. 1994 Oct 7;48(7):1437–1445. doi: 10.1016/0006-2952(94)90568-1. [DOI] [PubMed] [Google Scholar]
  14. De Azevedo W. F., Jr, Mueller-Dieckmann H. J., Schulze-Gahmen U., Worland P. J., Sausville E., Kim S. H. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735–2740. doi: 10.1073/pnas.93.7.2735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Drees M., Dengler W. A., Roth T., Labonte H., Mayo J., Malspeis L., Grever M., Sausville E. A., Fiebig H. H. Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin Cancer Res. 1997 Feb;3(2):273–279. [PubMed] [Google Scholar]
  16. Feller N., Broxterman H. J., Währer D. C., Pinedo H. M. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FEBS Lett. 1995 Jul 17;368(2):385–388. doi: 10.1016/0014-5793(95)00677-2. [DOI] [PubMed] [Google Scholar]
  17. Flens M. J., Izquierdo M. A., Scheffer G. L., Fritz J. M., Meijer C. J., Scheper R. J., Zaman G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994 Sep 1;54(17):4557–4563. [PubMed] [Google Scholar]
  18. Fotsis T., Pepper M., Adlercreutz H., Fleischmann G., Hase T., Montesano R., Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2690–2694. doi: 10.1073/pnas.90.7.2690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Glossmann H., Presek P., Eigenbrodt E. Quercetin inhibits tyrosine phosphorylation by the cyclic nucleotide-independent, transforming protein kinase, pp60src. Naunyn Schmiedebergs Arch Pharmacol. 1981 Aug;317(1):100–102. doi: 10.1007/BF00506266. [DOI] [PubMed] [Google Scholar]
  20. Gottesman M. M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385–427. doi: 10.1146/annurev.bi.62.070193.002125. [DOI] [PubMed] [Google Scholar]
  21. Gugler R., Leschik M., Dengler H. J. Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):229–234. doi: 10.1007/BF00614022. [DOI] [PubMed] [Google Scholar]
  22. Heijn M., Hooijberg J. H., Scheffer G. L., Szabó G., Westerhoff H. V., Lankelma J. Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12–22. doi: 10.1016/s0005-2736(97)00003-5. [DOI] [PubMed] [Google Scholar]
  23. Higgins C. F. ABC transporters: from microorganisms to man. Annu Rev Cell Biol. 1992;8:67–113. doi: 10.1146/annurev.cb.08.110192.000435. [DOI] [PubMed] [Google Scholar]
  24. Hofmann J., Doppler W., Jakob A., Maly K., Posch L., Uberall F., Grunicke H. H. Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int J Cancer. 1988 Sep 15;42(3):382–388. doi: 10.1002/ijc.2910420313. [DOI] [PubMed] [Google Scholar]
  25. Hollman P. C., de Vries J. H., van Leeuwen S. D., Mengelers M. J., Katan M. B. Absorption of dietary quercetin glycosides and quercetin in healthy ileostomy volunteers. Am J Clin Nutr. 1995 Dec;62(6):1276–1282. doi: 10.1093/ajcn/62.6.1276. [DOI] [PubMed] [Google Scholar]
  26. Hollman P. C., van Trijp J. M., Buysman M. N., van der Gaag M. S., Mengelers M. J., de Vries J. H., Katan M. B. Relative bioavailability of the antioxidant flavonoid quercetin from various foods in man. FEBS Lett. 1997 Nov 24;418(1-2):152–156. doi: 10.1016/s0014-5793(97)01367-7. [DOI] [PubMed] [Google Scholar]
  27. Hooijberg J. H., Broxterman H. J., Heijn M., Fles D. L., Lankelma J., Pinedo H. M. Modulation by (iso)flavonoids of the ATPase activity of the multidrug resistance protein. FEBS Lett. 1997 Aug 18;413(2):344–348. doi: 10.1016/s0014-5793(97)00940-x. [DOI] [PubMed] [Google Scholar]
  28. Jedlitschky G., Leier I., Buchholz U., Center M., Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. Cancer Res. 1994 Sep 15;54(18):4833–4836. [PubMed] [Google Scholar]
  29. Kool M., de Haas M., Scheffer G. L., Scheper R. J., van Eijk M. J., Juijn J. A., Baas F., Borst P. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 1997 Aug 15;57(16):3537–3547. [PubMed] [Google Scholar]
  30. Krishnamachary N., Ma L., Zheng L., Safa A. R., Center M. S. Analysis of MRP gene expression and function in HL60 cells isolated for resistance to adriamycin. Oncol Res. 1994;6(3):119–127. [PubMed] [Google Scholar]
  31. Kühnau J. The flavonoids. A class of semi-essential food components: their role in human nutrition. World Rev Nutr Diet. 1976;24:117–191. [PubMed] [Google Scholar]
  32. Lanzetta P. A., Alvarez L. J., Reinach P. S., Candia O. A. An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem. 1979 Nov 15;100(1):95–97. doi: 10.1016/0003-2697(79)90115-5. [DOI] [PubMed] [Google Scholar]
  33. Loe D. W., Deeley R. G., Cole S. P. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 1998 Nov 15;58(22):5130–5136. [PubMed] [Google Scholar]
  34. Loe D. W., Stewart R. K., Massey T. E., Deeley R. G., Cole S. P. ATP-dependent transport of aflatoxin B1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol. 1997 Jun;51(6):1034–1041. doi: 10.1124/mol.51.6.1034. [DOI] [PubMed] [Google Scholar]
  35. Losiewicz M. D., Carlson B. A., Kaur G., Sausville E. A., Worland P. J. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun. 1994 Jun 15;201(2):589–595. doi: 10.1006/bbrc.1994.1742. [DOI] [PubMed] [Google Scholar]
  36. Lyubimov E., Lan L. B., Pashinsky I., Ayesh S., Stein W. D. Saturation reversal of the multidrug pump using many reversers in low-dose combinations. Anticancer Drugs. 1995 Dec;6(6):727–735. doi: 10.1097/00001813-199512000-00003. [DOI] [PubMed] [Google Scholar]
  37. Markovits J., Linassier C., Fossé P., Couprie J., Pierre J., Jacquemin-Sablon A., Saucier J. M., Le Pecq J. B., Larsen A. K. Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res. 1989 Sep 15;49(18):5111–5117. [PubMed] [Google Scholar]
  38. Müller M., Meijer C., Zaman G. J., Borst P., Scheper R. J., Mulder N. H., de Vries E. G., Jansen P. L. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci U S A. 1994 Dec 20;91(26):13033–13037. doi: 10.1073/pnas.91.26.13033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nooter K., Westerman A. M., Flens M. J., Zaman G. J., Scheper R. J., van Wingerden K. E., Burger H., Oostrum R., Boersma T., Sonneveld P. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995 Nov;1(11):1301–1310. [PubMed] [Google Scholar]
  40. Senderowicz A. M., Headlee D., Stinson S. F., Lush R. M., Kalil N., Villalba L., Hill K., Steinberg S. M., Figg W. D., Tompkins A. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998 Sep;16(9):2986–2999. doi: 10.1200/JCO.1998.16.9.2986. [DOI] [PubMed] [Google Scholar]
  41. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  42. Srivastava A. K. Inhibition of phosphorylase kinase, and tyrosine protein kinase activities by quercetin. Biochem Biophys Res Commun. 1985 Aug 30;131(1):1–5. doi: 10.1016/0006-291x(85)91761-9. [DOI] [PubMed] [Google Scholar]
  43. Stinson S. F., Hill K., Siford T. J., Phillips L. R., Daw T. W. Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection. Cancer Chemother Pharmacol. 1998;42(4):261–265. doi: 10.1007/s002800050815. [DOI] [PubMed] [Google Scholar]
  44. Versantvoort C. H., Broxterman H. J., Lankelma J., Feller N., Pinedo H. M. Competitive inhibition by genistein and ATP dependence of daunorubicin transport in intact MRP overexpressing human small cell lung cancer cells. Biochem Pharmacol. 1994 Sep 15;48(6):1129–1136. doi: 10.1016/0006-2952(94)90149-x. [DOI] [PubMed] [Google Scholar]
  45. Versantvoort C. H., Broxterman H. J., Pinedo H. M., de Vries E. G., Feller N., Kuiper C. M., Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992 Jan 1;52(1):17–23. [PubMed] [Google Scholar]
  46. Versantvoort C. H., Schuurhuis G. J., Pinedo H. M., Eekman C. A., Kuiper C. M., Lankelma J., Broxterman H. J. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer. 1993 Nov;68(5):939–946. doi: 10.1038/bjc.1993.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Walgren R. A., Walle U. K., Walle T. Transport of quercetin and its glucosides across human intestinal epithelial Caco-2 cells. Biochem Pharmacol. 1998 May 15;55(10):1721–1727. doi: 10.1016/s0006-2952(98)00048-3. [DOI] [PubMed] [Google Scholar]
  48. Zaman G. J., Flens M. J., van Leusden M. R., de Haas M., Mülder H. S., Lankelma J., Pinedo H. M., Scheper R. J., Baas F., Broxterman H. J. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8822–8826. doi: 10.1073/pnas.91.19.8822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zaman G. J., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude Elferink R. P., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7690–7694. doi: 10.1073/pnas.92.17.7690. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES